Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarker-Directed Phase 2 Trial of Tamibarotene in Adult AML or MDS
2017-000783-14Phase 2Active
- Sponsor
- Syros Pharmaceuticals
- Start
- Nov 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tamibarotene in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (4 arms), sponsored by Syros Pharmaceuticals. Primary endpoints: Overall response rate in AML/higher-risk MDS (all-comers) and Transfusion independence rate in MDS (Arm 3). Started Nov 2017; status: active.
02
Drugs
tamibarotene
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2017-000783-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000783-14.